The Pancreatic Cancer Detection Consortium (PCDC) develops and tests new molecular and imaging biomarkers to detect early stage pancreatic ductal adenocarcinoma (PDAC) and its precursor lesions. These biomarkers would be used to identify individuals who are at high risk of developing PDAC and are candidates for early intervention.
Read more About PCDC.
Teams
- Beckman Research Institute, City of Hope Comprehensive Cancer Center/Translational Genomics Research Institute
- Dana Farber Cancer Institute/Harvard Medical School
- Johns Hopkins University
- Mayo Clinic/University of Pennsylvania
- Stanford University
- The University of Texas MD Anderson Cancer Center
- University of California, Davis
- University of Nebraska Medical Center
PCDC Resources and Collaborative Opportunities
- Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC)
- Alliance of Pancreatic Cancer Consortia for Biomarkers for Early Detection
Read more about PCDC Resources and Collaborative Opportunities
Administration
- Structure
- Steering Committee
- Consortium Coordinator
- NCI Program Staff
Funding Opportunities
NCI-sponsored Funding Opportunity Announcements (FOAs) related to PCDC include:
- Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional) – expires June 12, 2024
PAR-21-334 - Pancreatic Cancer Detection Consortium: Management and Data Coordination Unit (U24 Clinical Trial Not Allowed) – expires October 1, 2022
PAR-21-335
News and Events
PCDC EDRN-APaCC Joint (Virtual) Meeting
Date Posted: November 9, 2021
Could A Diabetes Diagnosis Help Detect Pancreatic Cancer Early?
Date Posted: July 7, 2021
The Search for Early Detection of Pancreatic Cancer Accelerates with Biomarkers
Date Posted: April 27, 2021
Pancreatic Cysts Are Monitored in New Trial Aimed at Reducing Cancer Risk Through Targeted Screening
Date Posted: April 8, 2021
New Onset Diabetes Cohort Sought to Unravel Complexities of Pancreatic Cancer Development
Date Posted: November 19, 2019